Gilead’s Covid-19 treatment Veklury props up first quarter gains amid $2.7B Trodelvy writedown

Gilead got a sales boost from its Covid-19 treatment for the first quarter — to the tune of $1.5 billion. The likely temporary bump came just in time though as Gilead reassessed its cancer drug Trodelvy’s value and took a $2.7 billion R&D impairment charge.